Company Filing History:
Years Active: 2013-2015
Title: Dirk Winkler: Innovator in Kynurenine-3-Monooxygenase Inhibitors
Introduction
Dirk Winkler is a notable inventor based in Hamburg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of kynurenine-3-monooxygenase (KMO) inhibitors. With a total of 4 patents to his name, Winkler's work is paving the way for new treatments for neurodegenerative disorders.
Latest Patents
Winkler's latest patents focus on certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. These patents describe various chemical entities that can be used in pharmaceutical compositions, which include at least one chemical entity and one or more pharmaceutically acceptable vehicles. The methods outlined in these patents aim to treat patients suffering from diseases and disorders that respond to the inhibition of KMO activity. This includes neurodegenerative disorders such as Huntington's disease. The patents also detail methods for screening compounds capable of inhibiting KMO activity, providing a comprehensive approach to treatment.
Career Highlights
Dirk Winkler is currently associated with the CHDI Foundation, Inc., where he continues to advance his research and development efforts. His work is instrumental in exploring innovative solutions for complex medical challenges. Winkler's dedication to his field is evident through his ongoing contributions to pharmaceutical science.
Collaborations
Winkler collaborates with talented professionals in his field, including Celia Dominguez and Leticia M Toledo-Sherman. These collaborations enhance the research and development process, fostering an environment of innovation and discovery.
Conclusion
Dirk Winkler's contributions to the field of pharmaceuticals, particularly in the area of KMO inhibitors, highlight his role as a leading inventor. His work not only addresses critical medical needs but also sets the stage for future advancements in treatment options for neurodegenerative disorders.